Preston K. Ratliff II is Chair of the Firm’s Litigation practice in New York. Mr. Ratliff focuses his practice on complex, high-stakes patent litigation with an emphasis on the biotechnology, pharmaceutical, chemical, agricultural, and renewable fuel sectors. He has successfully represented major and emerging companies both pre-trial and at trial. Mr. Ratliff has extensive experience counseling clients with respect to their intellectual property portfolios and evaluating strategic licensing opportunities.
AWARDS AND EXEMPLARY REPRESENTATIONS
Paul Hastings Nominated for Four LMG Life Sciences Awards
July 26, 2019
Paul Hastings Recognized in 2019 Managing Intellectual Property’s IP Stars
June 24, 2019
Paul Hastings Recognized in 2019 IAM Patent 1000 as One of the Most Sophisticated Patent Litigation Practices
June 07, 2019
Paul Hastings Wins Top Honors at 2019 Managing IP Americas Awards
April 08, 2019
Paul Hastings Scores Top Rankings in LMG Life Sciences for 2018
October 11, 2018
Paul Hastings Wins Hatch-Waxman Litigation Firm of the Year at LMG Life Sciences Awards
September 13, 2018
Paul Hastings Recognized in 2018 Managing Intellectual Property IP Stars
June 18, 2018
Paul Hastings Recognized in 2018 IAM Patent 1000 For Superb Track Record in Patent Litigation
June 15, 2018
Paul Hastings Recognized in 2017 IAM Patent 1000 for Pristine Patent Litigation Track Record
August 08, 2017
FDA “Supercharges” Paragraph IV Certifications List, Adding to Its Usefulness as a Resource
July 25, 2019
Federal Circuit Speaks on Patent Eligibility of Method-of-Treatment Claims: Key Takeaways from the Vanda v. West-Ward Decision
April 16, 2018
Federal Circuit Provides Additional Guidance for Induced Infringement in Hatch-Waxman Cases
November 13, 2017
U.S. Supreme Court Limits Venue Under the Patent Statute in TC Heartland
May 23, 2017
Minority Powerbrokers Q&A: Paul Hastings' Preston Ratliff
February 10, 2015
Intellectual Property Concerns (Part I)
May 17, 2013
New Jersey District Court Holds That a Claim for Infringement Under 35 U.S.C. § 271(e)(2) May be Stated Without a Paragraph IV Certification
February 21, 2013
Federal Circuit Vacates Injunction Against Generic Drug Manufacturer, Determining That A Settlement Agreement Term Is Ambiguous
December 29, 2010
FDA Revokes Final ANDA Approval, Determining That a Preliminary Injunction Extends the 30 Month Stay
September 22, 2010
Will Inequitable Conduct Finally Be Reformed?
July 06, 2010
The Federal Circuit to Address the Inequitable Conduct Doctrine En Banc for the First Time in Over 20 Years
April 27, 2010
A Generic Drug Manufacturers Prior Voluntary and Persistent Participation as a Litigant in Delaware is No Guarantee of Jurisdiction
February 24, 2010
Exergen: Putting a Crimp on Inequitable Conduct?
December 02, 2009
Recognized by Managing IP as the Life Sciences IP Litigation Firm of the Year
Paul Hastings was was recognized by Managing IP at their Americas Awards, which honored individuals and companies behind the most innovative and challenging IP work of the past year, as well as those driving the international IP market.
The firm was recognized as Life Sciences IP Litigation Firm of the Year in the United States.
April 05, 2019
Recognized as the 2019 Post-Grant Firm of the Year by IAM Magazine
Paul Hastings was recognized as the Post-Grant Firm of the Year at Intellectual Asset Management's inaugural Global IP Awards. The award recognizes the achievements of the firm's Patent Trial and Appeal Board (PTAB) Team, which practices before the US Patent & Trial Office. Over the past year, the team's accomplishments include numerous post-grant proceeding victories for technology and life sciences clients - four of which were affirmed by the Court of Appeals for the Federal Circuit.
January 30, 2019
Recognized as LMG Life Sciences Stars for 2018
Paul Hastings was recognized in the 2018 edition of LMG Life Sciences, with Highly Recommended rankings for General Patent Litigation and Hatch-Waxman Branded Litigation. LMG Life Sciences selected seven individual lawyers as "Life Sciences Stars," including Eric Dittmann, Gary Giampetruzzi, Naveen Modi, Joseph O’Malley, Chad Peterman, Preston Ratliff, and Bruce Wexler. Earlier this year, LMG Life Sciences honored the firm with the LMG Life Sciences award for Hatch-Waxman Litigation Firm of the Year – Branded.
October 12, 2018
Recognized as the Hatch-Waxman Litigation Firm of the Year by LMG Life Sciences
LMG Life Sciences announced that the firm’s Intellectual Property practice was honored at the LMG Life Sciences Awards as the Hatch-Waxman Litigation Firm of the Year (Branded). The publication cited the firm for wins on behalf of Sunovion Pharmaceuticals, which locked in compound patent protection for Latuda®, the company’s billion-dollar-plus-per-year schizophrenia and bipolar drug, after a judgment of infringement that was affirmed by the Federal Circuit; and for Orexigen Therapeutics after a trial victory where the judge found all three patents-in-suit to be valid and infringed. The firm was also noted for obtaining an unprecedented six walk-away consent judgments in a major pharmaceutical litigation.
The firm and its partners were also shortlisted for:
* Inter-Partes Review Firm of the Year
* Post Grant Proceedings Attorney of the Year: Naveen Modi
* General Patent Litigator of the Year – New York: Bruce Wexler
September 13, 2018
Paul Hastings IP Practice Honored in 2017 IAM Patent 1000
Intellectual Asset Management highlighted Paul Hastings' IP practice in IAM Patent 1000: The World's Leading Patent Professionals. The guide ranked the firm's practices Nationwide as well as in New York and Washington, DC. Paul Hastings partners were ranked in California: Yar Chaikovsky; New York: Joseph O'Malley; Gerald Flattmann; Preston Ratliff; Bruce Wexler; Samuel Waxman; Washington DC: Naveen Modi; Blair Jacobs; Joseph Palys; and Allan Soobert; and in Japan: Hiroyuki Hagiwara. Paul Hastings attorneys were also recognized in IAM's Nationwide tables: Yar Chaikovsky and Blair Jacobs were recommended for International Trade Commission litigation; Jacobs was recommended for his experience in Federal Circuit appellate litigation; and Naveen Modi and Joseph Palys were both recognized for their strength in post-grant proceedings. Preston Ratliff was also noted in the IAM Strategy 300, which recognizes individuals for their work in protecting intellectual property as a key business asset.
June 06, 2017
Paul Hastings IP Practice Honored in 2016 IAM Patent 1000
Intellectual Asset Management highlighted Paul Hastings' IP practice in its IAM Patent 1000: The World’s Leading Patent Professionals 2016. The guide ranked the firm’s Nationwide, New York, Washington, D.C., and Georgia IP practices; and partners Yar Chaikovsky, Gerald Flattmann, Blair Jacobs, Robin McGrath, Naveen Modi, Joseph O'Malley, Joseph Palys, Preston Ratliff, Samuel Waxman, and Bruce Wexler were recognized as leading lawyers.
May 27, 2016
Paul Hastings IP Practice Honored in 2015 IAM Patent 1000
Intellectual Asset Management highlighted Paul Hastings' IP practice in its IAM
Patent 1000: The World’s Leading Patent Professionals 2015. The guide ranked the firm’s Nationwide, New York, and Washington, D.C. IP practices; and partners Yar Chaikovsky, Gerald Flattmann, Blair Jacobs, Naveen Modi, Joseph O'Malley, Steven Park, Jeff Randall, Preston Ratliff, Allan Soobert, and Bruce Wexler were recognized as leading lawyers.
June 17, 2015
Legal Media Group's 2013 LMG Life Science Awards
The firm was nominated as a 2013 LMG Life Science nominee in the “Litigation Team of the Year” and “(General) Patent Litigation: Firm of the Year” categories.
August 12, 2013
Law360, Rising Stars 2012
Partner Preston Ratliff was named one of the Law360's five Rising Stars for 2012 in the Intellectual Property field.
April 06, 2012
Intellectual Property Magazine
Intellectual Property Magazine recognized Paul Hastings' IP Pharmaceutical Team as the Pharmaceutical Team of the Year.
November 30, 2010